Two-field Versus Three-field Lymphadenectomy in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement
Comparison of Lymph Node Dissection Results and Prognosis in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement: Two-field Versus Three-field Lymph Node Dissection
Sponsor: Chinese Academy of Medical Sciences
Listed as NCT02448953, this NA trial focuses on Esophageal Cancer and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Jan 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Jan 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status NA
-
Dec 2022 — Oct 2023 [monthly]
Unknown Status NA
▶ Show 5 earlier versions
-
Nov 2022 — Dec 2022 [monthly]
Unknown Status NA
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status NA
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences
- Fujian Cancer Hospital
- Hebei Medical University Fourth Hospital
- Henan Cancer Hospital
- Liaoning Cancer Hospital & Institute
- Peking University Cancer Hospital & Institute
- Shanghai Chest Hospital
- Sichuan Cancer Hospital and Research Institute
- Tang-Du Hospital
- Tongji Hospital
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .